



**University of  
Zurich**<sup>UZH</sup>

**Zurich Open Repository and  
Archive**

University of Zurich  
University Library  
Strickhofstrasse 39  
CH-8057 Zurich  
[www.zora.uzh.ch](http://www.zora.uzh.ch)

---

Year: 2003

---

## **FemABX peptidyl transferases: a link between branched-chain cell wall peptide formation and beta-lactam resistance in gram-positive cocci**

Rohrer, S ; Berger-Bächi, B

DOI: <https://doi.org/10.1128/AAC.47.3.837-846.2003>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-61924>

Journal Article

Published Version

Originally published at:

Rohrer, S; Berger-Bächi, B (2003). FemABX peptidyl transferases: a link between branched-chain cell wall peptide formation and beta-lactam resistance in gram-positive cocci. *Antimicrobial Agents and Chemotherapy*, 47(3):837-846.

DOI: <https://doi.org/10.1128/AAC.47.3.837-846.2003>

## MINIREVIEW

# FemABX Peptidyl Transferases: a Link between Branched-Chain Cell Wall Peptide Formation and $\beta$ -Lactam Resistance in Gram-Positive Cocci

S. Rohrer and B. Berger-Bächi\*

*Institute of Medical Microbiology, University of Zürich, CH-8028 Zürich, Switzerland*

Peptidoglycan biosynthesis is one of the preferred targets for antibiotics, as peptidoglycan is unique to eubacteria and inhibition of its production is generally bactericidal (Fig. 1). Peptidoglycan, the major component of the bacterial cell wall, forms the murein sacculus, a giant macromolecule that surrounds the cell as a single, flexible meshwork and is intimately involved in cell division. Its structure determines cell shape and maintains cell integrity by protecting it against the high internal osmotic pressure. The most widely used class of antibiotics that target the cell wall are  $\beta$ -lactams and their derivatives. Their introduction into therapy has, however, invariably been followed by the development and spread of resistance in the bacterial community. Gram-positive bacteria have developed two main strategies against  $\beta$ -lactams: drug inactivation by  $\beta$ -lactamases and intrinsic resistance mediated by modified, low-affinity variants of the target enzymes, the so-called penicillin-binding proteins (PBPs). To reach high-level  $\beta$ -lactam resistance, the low-affinity PBPs of staphylococci and pneumococci, in particular, depend on correctly synthesized peptidoglycan precursors. Specifically, the interpeptide structure, which is characteristic of the peptidoglycan of many gram-positive organisms (Fig. 1; Table 1), has a great impact on the level of  $\beta$ -lactam resistance that is achieved, as will be discussed below.

**Mechanism of  $\beta$ -lactam action.**  $\beta$ -Lactams target the extracellular steps of peptidoglycan biosynthesis by inhibiting the PBPs that catalyze the transpeptidation reaction, the last step in peptidoglycan synthesis (Fig. 1). Their localization at the outer face of the cytoplasmic membrane makes PBPs a readily accessible target.  $\beta$ -Lactams accomplish inhibition of PBPs by their structural similarity to the extended conformation of the terminal D-Ala<sub>2</sub> dipeptide of the peptide moiety of peptidoglycan (104). The active site of PBPs is rapidly acylated by the  $\beta$ -lactam, but the deacylation step is so slow that the proteins are terminally inactivated (37). Autolytic enzymes then trigger cell death under the influence of  $\beta$ -lactams (105). In *Staphylococcus aureus*, cell death occurs due to puncturing of the cell wall by the autolytic enzymes of the so-called splitting system (101), as the initiation of a new septum is inhibited, but the cell division cycle continues as scheduled. Bacteriolysis subsequently occurs when the cells are already dead (38).

PBPs belong to the protein superfamily of penicilloyl serine transferases, which also includes  $\beta$ -lactamases and  $\beta$ -lactam receptors such as BlaR1. All members of this protein family contain three common, conserved motifs, SXXK, (S/Y)X(N/C), and (K/H)(T/S)G, which together form the active site. Although the primary sequence can be highly divergent,  $\beta$ -lactam receptors and serine  $\beta$ -lactamases are considered to have evolved from PBPs, with  $\beta$ -lactamases having acquired the ability to rapidly hydrolyze the penicilloyl-enzyme intermediate, resulting in destruction of the  $\beta$ -lactam (37).

### LOW-AFFINITY PENICILLIN-BINDING PROTEINS MEDIATING $\beta$ -LACTAM RESISTANCE

**Staphylococci.** Methicillin-resistant *S. aureus* (MRSA) isolates appeared shortly after the introduction of methicillin, the first penicillinase-resistant  $\beta$ -lactam to come into clinical use, which was in 1960 (5). Methicillin resistance is due to the acquisition of SCCmec (staphylococcal cassette chromosome mec [51], formerly termed the *mec* determinant). SCCmec is considered a novel type of mobile element that has been termed a “resistance island,” in analogy to pathogenicity islands (54, 58). SCCmec is thought to be of nonstaphylococcal origin, as it differs from the rest of the staphylococcal chromosome in its G+C content. However, its reservoir has not been clearly identified. Several SCCmec subtypes have been characterized (4, 51, 63) that differ in their sizes, genes, and the additional resistance determinants that they contain, as well as in their clonal distributions. The gene responsible for methicillin resistance, *mecA*, encodes an additional PBP, PBP2' (synonym PBP2a), that has a lower affinity to methicillin and other  $\beta$ -lactam derivatives.

One of the characteristic features of methicillin resistance is its heterogeneity; in a given population of *S. aureus*, the majority of cells are often resistant to a relatively low concentration of methicillin, while a small proportion ( $10^{-8}$  to  $10^{-2}$  of the cells) are able to grow at higher concentrations. This heterogeneity is the reason for the failure of  $\beta$ -lactam therapy in MRSA infections. It has been demonstrated that the level of resistance does not necessarily correlate with the amount of PBP2' expressed (86), but there is no satisfactory genetic or biochemical explanation for this phenomenon, although many mutations leading from high-level resistance to heteroresistance in vitro have been identified (for a review, see reference 11).

In the absence of the *mecA* gene, staphylococci may acquire

\* Corresponding author. Mailing address: Institute of Medical Microbiology, University of Zürich, Gloriastr. 32, CH-8028 Zürich, Switzerland. Phone: 0041 1 634 26 50. Fax: 0041 1 634 49 06. E-mail: bberger@immv.unizh.ch.




FIG. 1. Pathway and inhibitors of peptidoglycan synthesis in *S. aureus* (adapted in part from references 17 and 111). (I) The assembly of the lipid II precursor is universal for eubacteria; the MurA reaction is the first step committed to peptidoglycan synthesis (17, 111). (II) The interpeptide is synthesized on the membrane-bound precursor. (III and IV) Extracellular steps catalyzed by transglycosylases and transpeptidases (PBPs) lead to mature peptidoglycan.

$\beta$ -lactam resistance via mutations that lead to overexpression of endogenous PBP2 and/or PBP4 or mutations that reduce their penicillin affinities (43, 50). Clinical *S. aureus* isolates with such mutations have been identified and have been termed MODSA in reference to their modified PBPs (106). Furthermore, a decreased affinity of PBP3 for  $\beta$ -lactams was found to lead to low-level methicillin resistance in *Staphylococcus epidermidis* (78). Overexpression of a penicillinase in a specific genetic background, in the so-called borderline resistant *S. aureus* (BORSA), may also lead to low-level methicillin resistance (6). These two types of resistance mechanisms have less clinical impact than true methicillin resistance in *S. aureus* and were never observed to achieve more than borderline resistance in clinical isolates.

**Pneumococci.** In *Streptococcus pneumoniae*, target alteration is the main mechanism of resistance to penicillin. In contrast to methicillin resistance in staphylococci, penicillin resistance arises by modification of endogenous PBPs. The first PBPs to be affected are PBP2b or the essential PBP, PBP2x, depending on the antibiotic used for selection (41, 59). Mutations in just three amino acids in the active-site region of PBP2x are sufficient to create low-affinity derivatives (55). Additional gene

diversity is created by horizontal exchange of DNA fragments between strains or even with commensal streptococci, resulting in highly mosaic genes. Some very low affinity PBP2x variants from clinical isolates contain more than 100 amino acid substitutions spread over the entire sequence (47, 61, 83). Mutations in PBP2x and PBP2b are sufficient for midlevel resistance, but to achieve high-level penicillin resistance, all six endogenous PBPs can be modified. The combination of several highly resistant PBPs may raise the penicillin MIC 100- to 1,000-fold (45, 114). Similar to staphylococci, it was found that additional genes other than *pbp* genes are involved in pneumococcal  $\beta$ -lactam resistance, as transformation of susceptible strains with only the *pbp* genes from highly resistant strains was not sufficient to achieve the same level of resistance (46, 96).

**Enterococci.** Enterococci are naturally less susceptible to  $\beta$ -lactams than pneumococci or staphylococci (35). Their intrinsic  $\beta$ -lactam resistance is due to endogenous low-affinity PBP5, which is not essential (91). Acquired resistance to higher antibiotic concentrations is associated with the overproduction of PBP5 and/or a decreased affinity of PBP5 for the  $\beta$ -lactam (34). However, the role of PBP5 in high-level resistance is likely to depend on additional factors. The expression of *pbp5*

TABLE 1. All species of grampositive bacteria found to have a FemABX homolog also bear an interpeptide in their peptidoglycan

Species	Interpeptide	Peptidyl transferase (FemABX homolog), accession no.	Reference(s)
<i>Staphylococcus aureus</i>	Gly <sub>5</sub>	FemA, P14304; FemB, P14305; FmhB, AAD23961; FmhA, AAD23960; FmhC, AAD23963	10, 49, 84, 88, 109
<i>Staphylococcus epidermidis</i>	Gly <sub>2-3</sub> -L-Ser <sub>1-2</sub> , L-Ala-Gly <sub>4</sub>	FemA, JC5325; FemB, JC5326	1, 52, 88
<i>Staphylococcus</i> spp.	Gly <sub>5</sub> , Gly <sub>2-3</sub> -L-Ser <sub>1-2</sub> , L-Ala-Gly <sub>4</sub>	<i>S. anaerobius</i> FemA, AAD33940; <i>S. capitis</i> FemA, AAC69633; <i>S. cohnii</i> FemA, AAD45259; <i>S. gallinarum</i> FemA, AAD45258; <i>S. haemolyticus</i> FemA, AAC69631; <i>S. hominis</i> FemA, CAA73372; <i>S. intermedius</i> FemA, AAD33941; <i>S. lugdunensis</i> FemA, AAC69632; <i>S. saprophyticus</i> FemA, CAA73373; <i>S. schleiferi</i> FemA, AAC69636; <i>S. sciuri</i> FemA, AAC69635; <i>S. xylosum</i> FemA, AAC69634; <i>S. warneri</i> FemA, AAD33942; <i>S. haemolyticus</i> FemB, AAD22133; <i>S. simulans</i> Lf, AAB53784; <i>S. capitis</i> Epr, BAA21486; <i>S. sciuri</i> Epr, AAG16879;	
<i>Streptococcus pneumoniae</i>	L-Ala-L-Ser, L-Ala <sub>2</sub>	FibA, CAB89120; FibB, CAB89121; MurMN, AJ250764	33, 88, 114
<i>Streptococcus mutans</i>	L-Thr-L-Ala		88
<i>Streptococcus pyogenes</i>	L-Ala <sub>2-3</sub>		88
<i>Streptococcus thermophilus</i>	L-Ala <sub>2-3</sub>	AAK18829	88
<i>Streptococcus zooepidemicus</i>	L-Ala <sub>2-3</sub>	Zif, AAC46073	7, 88
<i>Streptococcus equi</i>	L-Ala <sub>2-3</sub>		
<i>Streptococcus milleri</i>	L-Thr-Gly	MilF, AF243359	13, 88
<i>Enterococcus faecalis</i>	L-Ala <sub>2-3</sub>		16, 88
<i>Clostridium perfringens</i>	Gly	BAB81796	88
<i>Streptomyces</i> spp.	Gly	<i>S. coelicolor</i> , CAB45460; <i>S. toyocaensis</i> StaO, AAM80555	81, 88
<i>Weissella viridescens</i> ( <i>Lactobacillus viridescens</i> )	L-Ala-L-Ser	AAG21689	48, 88
<i>Deinococcus radiodurans</i>	Gly <sub>2</sub>	AAF10635	88
<i>Treponema pallidum</i>	Gly	AAC65773	110
<i>Borrelia</i> spp.	Gly	AAB91521	115

alleles from highly resistant strains in a penicillin-susceptible *pbp5* deletion mutant of *Enterococcus faecium* conferred only moderate, not high-level, resistance (91). As the sensitive PBPs are inactivated by  $\beta$ -lactams, PBP5 is able to synthesize mucopeptide dimers and trimers in abundance, but higher oligomers are reduced (92). Inactivation of PBP5 of *Enterococcus faecalis* leads to hypersusceptibility to all  $\beta$ -lactams (93). Interestingly, the first low-affinity PBP found to be located on a plasmid is PBP3r from *Enterococcus hirae*, which is almost identical to PBP5 (80, 82).

#### STRUCTURAL CHARACTERISTICS OF NORMAL AND LOW-AFFINITY PBPS

Depending on the species, bacteria contain between four and eight PBPs, which are divided into several classes (39). Monofunctional PBPs contain a penicillin-binding (PB) domain and largely perform accessory functions in peptidoglycan synthesis. Class A multimodular, bifunctional PBPs contain a non-PB (n-PB) module that has transglycosylase activity, which has been demonstrated for PBP1a and PBP1b in *Escherichia coli* (71) and PBP2 in *S. aureus* (79). The PB domains of class

A PBPs perform the transpeptidase function. Class A PBPs can therefore perform all necessary functions in peptidoglycan cross-linking.

Class B multimodular PBPs contain an n-PB domain which does not appear to have transglycosylase activity and a PB domain which has transpeptidase activity. The exact function of the n-PB module is unknown, but it may mediate interaction with other proteins of the cell wall synthesis machinery (53) and it is essential for folding (39). The low-affinity PBPs of enterococci and staphylococci are closely related and form PBP subclass B1, which stands apart from the unmodified class B PBPs and also from *S. pneumoniae* PBP2x (39). As an exception, *Bacillus subtilis* PBP3 groups in the B1 cluster but has not been linked to any low-affinity property (70). Class B PBPs must cooperate with either a monofunctional transglycosylase or the transglycosylase domain of a class A PBP to synthesize cross-linked peptidoglycan. In *S. aureus*, this assumption was recently supported by the observation that PBP2' needs the intact transglycosylase module of the resident PBP2 in order to confer methicillin resistance (79). However, there are indications that PBP2' is a very poor transpeptidase that only barely

allows the cells to survive the action of methicillin. When highly methicillin resistant *S. aureus* strain COL is grown in the presence of methicillin concentrations sufficient to inactivate the endogenous PBPs, PBP2' forms a poorly cross-linked cell wall containing mainly un-cross-linked muropeptides and only a few muropeptide dimers or trimers. The same strain grown in antibiotic-free medium produces highly cross-linked peptidoglycan (25).

Little is known about the structural changes that give rise to low-affinity PBPs. The recent determination of the structure of *E. faecium* PBP5fm, which belongs to the B1 group of PBPs, has provided some evidence into the mechanism that makes these proteins resistant to  $\beta$ -lactams. The active site of PBP5fm is surrounded by a number of amino acids that are strongly conserved in class B1 PBPs but not in PBPs of other classes and that may confer greater rigidity and a reduced affinity of  $\beta$ -lactams for the active site of this group of proteins (87).

In PBP2x from highly resistant strain SP328 (27), the helix that harbors the SXN motif is highly flexible, causing the serine to point away from the active site and leading to a decreased affinity for the antibiotic. Important amino acid exchanges are T338A in the STMK motif, which leads to a reduced rate of acylation by the  $\beta$ -lactam (27, 69). In a variant of PBP2x that has a higher affinity for penicillin (40), the active site lies in a deep groove of the protein. In contrast, the flexible architecture of PBP2x from resistant strain SP328 results in an "open" active-site pocket that may be able to accommodate branched peptidoglycan precursors (27), for which it apparently exhibits a substrate preference, as will be discussed below. Although kinetic studies of low-affinity PBP2x also demonstrated that it has a reduced affinity for a structural analog of the linear stem peptide (69, 117), studies with an analog of the branched stem peptide have not been done to confirm the substrate preference hypothesis.

#### LOW-AFFINITY PBPS AND VANCOMYCIN RESISTANCE

The recent first report of a vancomycin-resistant *S. aureus* isolate that has acquired the *vanA* gene from enterococci (19) raises a number of questions: does the incorporation of D-lactate into the peptidoglycan precursor affect the function of the cross-linking enzymes, particularly PBP2'? If yes, how does this affect resistance to agents other than vancomycin?

Some indications of the answers to this problem may be found in studies conducted with enterococci. It appears that the presence of D-lactate does not affect peptidoglycan cross-linking under unchallenged growth conditions (15, 21). However, vancomycin and  $\beta$ -lactams have been shown to exhibit a synergistic action in vancomycin-resistant enterococci, which indicates that their low-affinity PBPs do not cope well with the modified stem peptides (2, 42).

In a recent study with *S. aureus* (23), the addition of D-serine, D-threonine, and D-phenylalanine to the growth medium reduced the levels of cross-linking and methicillin resistance, as these amino acids were efficiently incorporated in the fifth position of the peptidoglycan stem peptide. The same effect has been observed when glycine was added to the growth medium (22). However, these experiments did not include D-lactate, and the effect on vancomycin resistance was not determined. Although the most recent of these studies concluded

that *vanA*-mediated vancomycin resistance and *mecA*-mediated methicillin resistance may be mutually exclusive, this hypothesis does not hold true for the recently reported vancomycin-resistant *S. aureus* strain that also carries *mecA* and for which the oxacillin MIC is 16  $\mu$ g/ml (19).

#### BIOSYNTHESIS OF BRANCHED CELL WALL PEPTIDES AND IMPACT ON $\beta$ -LACTAM RESISTANCE

Cross-linking of peptidoglycan (Fig. 1) by transpeptidases (PBPs) always occurs via a diamino acid in the stem peptide, generally *meso*-diaminopimelic acid, L-Lys, or L-Orn. Cross-links occur either directly or via an interceding spacer (or interpeptide), which consists of one to five amino acids and which branches off the diamino acid. The interpeptide may contain amino acids in the L or D conformation (88).

In *S. aureus*, the pentaglycine interpeptide is synthesized in a sequential fashion on the cytoplasmic face of the membrane, with lipid II as a substrate (57, 66), where the first glycine is attached to the  $\epsilon$ -amino group of L-lysine (56, 97). The glycine donor is glycyl-tRNA (65), and a fraction of tRNAs is exclusively used in interpeptide synthesis (18). Although tRNAs participate in interpeptide formation, the reaction is not inhibited by antibiotics that target protein translation, and thus, it was concluded that interpeptide synthesis is achieved by a nonribosomal mechanism (57). In an alternative pathway, in species such as *E. faecium*, whose interpeptide contains D-amino acids, the amino acids are incorporated from phosphate precursors (17, 88).

**FemABX protein family.** The branched peptide chain is synthesized by a family of nonribosomal peptidyl transferases (Fig. 2) that use either the lipid II-linked peptidoglycan precursor or, alternatively, the soluble, UDP-MurNAc-linked stem peptide (cf. Fig. 1) as a substrate for the addition of one or several additional amino acids to the peptidoglycan stem peptide in a sequential fashion. The impact of these factors on cell wall composition and, in clinically relevant species, on antibiotic resistance is outlined below.

**Staphylococcus.** The cause of heterogeneity in methicillin resistance was initially investigated by transposon-mediated mutagenesis (9), which led to the identification of a number of loci whose inactivation lowered the resistance level, and the terms *fem* factors (for factors essential for methicillin resistance) and *aux* factors (for auxiliary) were coined (8, 12, 26). It was shown that all *fem* factors are housekeeping genes, most of which play a role in cell wall biosynthesis. Mutation of the *femAB* operon affects the glycine content in the cell wall (64). It was determined that FemA specifically adds glycines 2 and 3 of the pentaglycine interpeptide, while FemB, which shares 39% identity and 59% similarity with FemA on the amino acid level, adds glycines 4 and 5 (28). *femAB* mutants completely lose resistance to methicillin and become hypersusceptible to many unrelated antibiotics (62). *femAB* mutant cells are pseudomulticellular with thickened cell walls and abnormal septa due to impaired cell wall turnover and are resistant to the glycyl-glycine endopeptidase lysostaphin (49). It is clear from these observations that not only low-affinity PBP2' but also the endogenous PBPs cope very badly with the shortened pentaglycine interpeptide. FemA and FemB homologs have been identified in all staphylococcal species tested (1, 112).





FIG. 2. Dendrogram of the FemABX protein family. Branch lengths are proportional to phylogenetic distances. Experimentally confirmed family members are shown in boldface type. The number of sequenced FemA homologs of *Staphylococcus* spp. has become quite large, and they are shown in an enlarged inset. The GenBank database was searched with the BLAST program (<http://www.ncbi.nlm.nih.gov/BLAST/>) (3) by using *S. aureus* FmhB as the query sequence. In the case of *Streptococcus equi* and *Streptococcus pyogenes*, three FemABX homologs were found, two of which are related to FibA/MurM of *S. pneumoniae* and one of which is related to FibB/MurN of *S. pneumoniae*. Unfinished microbial genomes were searched by using the tblastn program (<http://www.ncbi.nlm.nih.gov/ncbi/blast/unfinishedgenome.html>). Preliminary sequence data from unfinished genomes were obtained from The Institute for Genomic Research website at <http://www.tigr.org> and from the Sanger Center at <http://www.sanger.ac.uk>. In the case of MurM, where multiple, more than 90% identical alleles are available, one representative sequence (that of strain R36A) was chosen. Protein sequences were aligned by using the ClustalW program (102), and the dendrogram was constructed by using the TreeView program (75).

The factor (*femX*) that catalyzes the incorporation of the first glycine long remained elusive. Inactivation of *femA* or *femB* yielded viable cells, but it was demonstrated that they had acquired compensatory mutations in order to survive (62). It was deduced that the inactivation of *femAB* would otherwise be lethal and that the postulated *femX* was probably essential (60). The advent of whole-genome sequencing made it possible to search the complete *S. aureus* genome for additional homologs of *femAB*; and three sequences were identified and named *fmhA*, *fmhB*, and *fmhC* (for *fem* homolog) (109). *fmhA* and *fmhC* (alternative name, *eprH* [99]) were inactivated without a discernible phenotype, while inactivation was impossible for *fmhB*, making it a likely *femX* candidate (109). A promoter insertion strategy in which cells could be depleted of FmhB was used to demonstrate its role in the addition of glycine 1 of the interpeptide chain. FmhB depletion leads to the virtual disappearance of glycine-substituted mucopeptide monomers and to a significant reduction in the degree of peptidoglycan cross-linking. The introduction of this construct into an MRSA back-

ground causes a complete loss of resistance to methicillin (84). It can be concluded from these observations that the staphylococcal cell can tolerate, if barely, the reduction of the interpeptide to one glycine, but the complete lack of glycine substitution is lethal. In addition, PBP2', the low-affinity PBP responsible for methicillin resistance, is unable to perform its function in the absence of a five-membered interpeptide chain.

**Pneumococcus.** In *S. pneumoniae*, the peptide side chain, consisting of Ala<sub>2</sub> or Ser-Ala, is dispensable (90). In an early study of the pneumococcal cell wall, Garcia-Bustos and Tomasz (36) analyzed a number of penicillin-susceptible and -resistant clinical strains and observed branched as well as unbranched peptidoglycan stem peptides. While in resistant strains there was a large amount of Ala<sub>2</sub>- or Ser-Ala-substituted peptides, in susceptible strains, the situation was variable: in the clinical strains analyzed, the mucopeptides were predominantly unsubstituted, whereas in laboratory strain R6 there was a significant fraction of branched mucopeptides present. In both the susceptible and the resistant strains ana-

lyzed, the mucopeptide monomer fractions contained a detectable amount of nonsubstituted mucopeptides; but the dimer, trimer, and oligomer fractions appeared to contain almost exclusively substituted mucopeptides. These findings led to the conclusion that the PBPs exhibit a substrate preference for substituted stem peptides; the preference appeared more marked in resistant strains, which have modified, low-affinity PBPs. In a penicillin-resistant transformant of strain R6, nonbranched mucopeptide dimers were undetectable, leading Garcia-Bustos and Tomasz (36) to suggest that PBP2x may discriminate against unsubstituted stem peptides, a notion that has recently been supported by its crystal structure (discussed above).

The genes for the alanine and/or serine transferases of *S. pneumoniae* have recently been identified by two independent groups (33, 114) and named *murMN* and *fibAB*, respectively. Inactivation of these genes in penicillin-resistant strains results in greatly decreased levels of resistance to  $\beta$ -lactams (reductions of more than 32-fold), with a complete breakdown of resistance to cefoxitin, which predominantly targets PBP2x. The MIC is reduced twofold for penicillin-sensitive laboratory strain R6. In addition, the level of total cell wall cross-linking is reduced (114). As might be expected with such a weakened cell wall and in analogy to *femAB* mutants (62), *murMN* mutants are hypersusceptible to all other classes of cell wall synthesis inhibitors (32). Surprisingly, laboratory strain R36A contains a very small amount of alanine- or serine-substituted mucopeptides compared to the amounts in strain R6, even with an intact *murMN* operon (33). The *murM* and *murN* genes of laboratory strains R6 and R36A, which have essentially the same genetic backgrounds, differ in only two and one amino acid positions, respectively. It is conceivable that variations in the transcriptional activity of *murMN* may cause this significant difference in their peptidoglycan compositions.

As is the case with many genes in pneumococci (44, 45), the *murMN* genes, like PBP2x, exhibit a mosaic structure which may explain the strain-dependent differences in branched mucopeptide content. The variability of the *murMN* genes appears to be responsible for variations in the catalytic efficiencies of their products (30, 95). Again, in resistant strains, a larger amount of branched mucopeptides indicates that these strains contain *murM* alleles that encode a highly efficient enzyme. The presence of a high-efficiency *murM* allele appears to be a prerequisite for the acquisition of high-level resistance to penicillin by remodeled, low-affinity PBPs, as only transformation by both the low-affinity PBPs and the *murMN* genes from a resistant donor strain results in high-level resistance in a susceptible recipient (95).

The correlation between branched peptidoglycan and low-affinity PBPs as the sole resistance mechanisms may be questionable due to a report that dissociated penicillin resistance from branched peptidoglycan peptides by transformation (89). When a susceptible, directly cross-linked strain was transformed with DNA from a resistant donor with low-affinity PBPs and a branched-chain peptidoglycan, the first round of transformation resulted in resistant strains that had acquired both the branched peptides and the low-affinity PBPs of the donor. However, in a second round of transformation, resistance was no longer coupled to the branched-chain peptidoglycan, as the strains were resistant to penicillin but had retained the recipient's peptidoglycan structure. Examination of the

PBP profiles indicated that most of these second-round transformants had acquired changes, possibly point mutations, leading to PBPs with reduced  $\beta$ -lactam affinities. Conceivably, mutations in genes other than *murMN* or *pbp* were selected in these experiments; therefore, the study does not necessarily invalidate the link between resistance and peptidoglycan structure.

The description of *MurMN* in *S. pneumoniae* has given valuable insights into the specificity of the FemABX family of peptidyl transferases. Filipe et al. (31) have analyzed a set of *murM* alleles and pinpointed the region that determines which amino acid is incorporated into the peptidoglycan precursor. The exchange of codons 244 to 274 between *murM* alleles from two strains incorporating mainly seryl-alanine (strain KY17) or dialanine (strain DE1) determined the ratio of serine versus alanine that was incorporated. In particular, the amino acid in position 260 was determined as the major difference in these two strains. A single amino acid exchange (T260K) in *murM* of strain KY17, indeed, slightly increased the alanine content of the peptide side chain, but other residues in the region from codons 244 to 274 must be assumed to affect the specificity of *murM* as well. A Q27E/T mutation had no measurable effect, although it was suggested that this amino acid position may be involved in catalysis in FemX of *Weissella viridescens* (see below) (48). In addition, the deletion of as few as 50 amino acids at the N terminus or 10 amino acids at the C terminus inactivated *MurM*. This effect was also observed in the case of FemA and FemB of *S. aureus*, in which point mutations at the C terminus, which lead to a stop codon, completely inactivated the proteins (60).

***Lactobacillus.*** Hegde and Shrader (48) have recently identified FemX in *W. viridescens* (formerly *Lactobacillus viridescens*) and were able to reconstitute the addition of glycine to the soluble, UDP-linked peptidoglycan precursor from glycyl-tRNA in vitro. Their attempt to reconstitute the same reaction with *S. aureus* FmhB was unsuccessful, probably because this reaction occurs on lipid II, whereas in *W. viridescens* it occurs on the soluble precursor (cf. Fig. 1).

***Enterococcus.*** The catalytic activities of the FemABX homologs in *E. faecalis* have been analyzed (16). Two homologous open reading frames were found. Both *orf1* (coding for a protein of 48.3 kDa) and *orf2* (coding for a protein of 46 kDa) were recombinantly expressed and reconstituted in an in vitro assay. Only the product of *orf2* has UDP-MurNAc-pentapeptide:L-alanine ligase activity and therefore corresponds to *S. pneumoniae* *MurM*, to which it is closely related (Fig. 2). It is conceivable that a coupled reaction with *Orf1* and *Orf2* would demonstrate the activity of *Orf1*, which groups with *MurN* in Fig. 2. The effect of mutations of *orf1* and *orf2* on  $\beta$ -lactam resistance has not yet been determined.

**Endopeptidase resistance factors.** The family of FemABX-like proteins also includes immunity factors that protect producers of interpeptide-specific endopeptidases against their own products by substituting some of the amino acid positions in their interpeptides. *epr* (endopeptidase resistance) from *Staphylococcus capitis* (100) and *lif* (lysostaphin immunity factor) from *Staphylococcus simulans* bv. *staphylolyticus* (20, 103) incorporate serine into the interpeptide at specific positions and thereby make the cell wall resistant to glycyl-glycine endopeptidases such as lysostaphin (29, 108). Interestingly, the

incorporation of serine into the peptide side chain due to expression of *epr* in an MRSA background does not appear to affect methicillin resistance (100). This finding indicates that although PBP2' is dependent on a five-membered interpeptide bridge, it does not appear to discriminate between interpeptides consisting of glycine only or glycine and serine. Interestingly, the two additional FemABX homologs in *S. aureus*, FmhA and FmhC/EprH, are most closely related to Lif and Epr (Fig. 2). As mutation of these genes did not appear to cause a phenotype (99, 109), *fmhA* and *fmhC* may be silent or almost inactive remnants of genes encoding serine-incorporating enzymes in *S. aureus*. They may even be responsible for the somewhat elevated level of serine incorporation that was observed in a partial *femAB* mutant (24).

In *Streptococcus milleri*, the endopeptidase millericin B (*milB*) is coorganized with the immunity factor *milF*. MilF substitutes leucine in the interpeptide for the endogenous threonine (13). In *Streptococcus zooepidemicus*, zoocin (*zooA*) and its corresponding immunity factor, *zif*, have been described (94). However, it is unclear whether Zif substitutes any amino acids in the interpeptide (7).

#### ROLE OF BRANCHED-CHAIN PEPTIDES IN CELL DIVISION

In addition to their impact on  $\beta$ -lactam resistance, branched cell wall peptides play an important role in cell division. *femAB* mutants, which have a shortened interpeptide, exhibit thickened septa and are pseudomulticellular due to impaired cell separation (49). It has been shown that endogenous glycylglycine endopeptidases are involved in cell separation, and *femAB* mutants are largely resistant to the actions of such endopeptidases (98), which explains this defect in cell division. On the other hand, the major autolysin Atl, which is implicated in lytic death in the presence of penicillin (described above), is not impaired by the shortened interpeptide, as its mature domains have endo- $\beta$ -N-acetylglucosaminidase and N-acetylmuramyl-L-alanine amidase activities (101), and is not affected by the interpeptide structure.

#### ANCHORING OF CELL SURFACE PROTEINS

In addition to their influence on resistance to  $\beta$ -lactams and their crucial role in cell wall integrity and cell division, branched-chain mucopeptides also play a role in virulence. In *S. aureus*, important virulence factors are covalently attached to the cell wall interpeptide. Examples are protein A, fibrinogen-binding protein (clumping factor), and other so-called MSCRAMMs (microbial surface components recognizing adhesive matrix molecules) that enable adhesion to host tissues (73, 76). Branched side chains that do not participate in peptidoglycan cross-linking serve as anchoring points for such cell wall-linked proteins. Cell wall-localized proteins carry a characteristic C-terminal sorting signal with a conserved LPXTG sequence (72) that is recognized in *S. aureus* by the enzyme sortase (SrtA) (67). This enzyme tethers the proteins to the interpeptide in a transpeptidase reaction, which occurs on lipid II on the extracellular face of the membrane (77, 85). It has been shown that SrtA will not accept linear stem peptides lacking glycine as a substrate (85) and that with the shortened

interpeptides containing only one and three glycines in *femAB* and *femB* mutants, respectively, sorting of cell wall proteins is impaired (107). In sortase mutants (67, 68), virulence is reduced due to an impairment of the anchoring of cell surface proteins. In analogy, in *femAB* mutant strains, the truncated mucopeptide side chains are expected to cause a reduction in virulence due to the concurrent inhibition of the sorting reaction.

A second sortase, SrtB, was found to specifically link IsdC (encoded by the iron-responsive surface determinant locus of *S. aureus*) to the cell wall via an NPQTN sequence (68).

It may be assumed that in other species as well a sortase catalyzes attachment of proteins to the cell wall via the branched peptides. In *S. pneumoniae*, neuraminidase contains a sorting signal, and several cell wall-localized proteins in enterococci also contain this signature sequence (73). A sortase has indeed been described recently in *Listeria monocytogenes*, whose cell wall peptides are directly cross-linked via meso-diaminopimelic acid (14), indicating that the substrate requirements for each sortase correspond to the species' peptidoglycan structure.

#### CONCLUSION

The FemABX protein family has emerged as a broadly distributed group of peptidoglycan stem peptide peptidyl transferases. The interpeptide serves as a means for cross-linking of the cell wall, mediated by the PBPs. Some PBPs appear to exhibit a marked substrate preference for the peptide side chain, as may be the case with PBP2x in *S. pneumoniae*. In *S. aureus*, the PBPs are unable to function at all if the interpeptide is lost. The reduction in length or the absence of the interpeptide impairs the structure of the cell wall and renders  $\beta$ -lactam-resistant strains that rely on low-affinity PBPs susceptible to the antibiotics. A subgroup of FemABX family members serve as immunity factors in producers of interpeptide-specific endopeptidases. In addition, the interpeptide plays an important role in cell separation and virulence.

A database search for FmhB homologs yields related sequences in a wide range of bacterial genomes. Species as diverse as *Borrelia burgdorferi*, *Streptomyces coelicolor*, and *Clostridium perfringens* contain a FemABX homolog (Table 1; Fig. 2). It is not surprising that all species containing a FemABX homolog also bear a peptide side chain in their peptidoglycan (Table 1), which makes it likely that all homologs encode functional FemABX family proteins. However, the function of these FemABX homologs needs to be confirmed experimentally. Interestingly, in bacteria such as *Lactococcus lactis* or *E. faecium*, which contain D-amino acids in their interpeptides, no FemABX homolog can be found. These amino acids are presumed to be attached by an entirely different but not yet identified mechanism (17, 88).

It appears that the reduction of  $\beta$ -lactam affinity has incurred structural restraints on the remodeled PBPs of *S. aureus* and *S. pneumoniae*. Their modified active site may exhibit a substrate preference for peptidoglycan precursors with a branched peptide chain. Unfortunately, as only the structures of *S. pneumoniae* PBP2x and *E. faecium* PBP5fm have been solved, this remains speculation. The precise requirements for branched peptide peptidoglycan precursors for the resistance



level achieved in pneumococci, mediated by low-affinity PBPs with various levels of modification, will need to be carefully analyzed in an isogenic system. In addition, the importance of the branched peptide structure for  $\beta$ -lactam resistance in *E. faecalis* remains to be demonstrated.

The observation that *S. aureus* PBP2' and *E. faecium* PBP5 are poor transpeptidases if the sensitive PBPs are masked by  $\beta$ -lactams (25, 92) indicates that these "rescue transpeptidases" (87) have reduced their affinities to  $\beta$ -lactams at the cost of efficiency. If the activities of these PBPs are further impaired by a suboptimal substrate, they are simply unable to perform their functions under antibiotic pressure, as is shown by the fem-type mutations in *S. aureus* and *S. pneumoniae* and the synergism between vancomycin and  $\beta$ -lactams in vancomycin-resistant enterococci.

The global spread of antimicrobial resistance has created a need for new agents for the treatment of bacterial infections. The knowledge that has been gained about the FemABX family of proteins suggests that they are a suitable target for the development of new antimicrobials. If an inhibitor of FemABX proteins was developed, it would be a potent and highly specific antimicrobial agent in those organisms in which the interpeptide structure is essential (60). Alternatively, in organisms in which the peptidoglycan interpeptide is dispensable, such as penicillin-resistant pneumococci, a FemABX inhibitor would certainly restore the activities of  $\beta$ -lactams. As a supporting strategy, the virulence of epidemic strains could be reduced (74) by preventing the attachment of cell wall-linked proteins via inhibition of the FemABX homologs and subsequent impairment of sorting of these virulence factors. In addition, peptidoglycan itself has been identified as a virulence factor eliciting host responses (113, 116). In analogy to mutation of *femAB* (64), it is conceivable that inhibition of FemABX factors might lead to a reduction in cell wall turnover or peptidoglycan "shedding" and thus reduce virulence. In the near future, as broad-spectrum antimicrobials become increasingly unreliable, the use of a FemABX inhibitor might be an option to be explored.

#### ACKNOWLEDGMENTS

Research in the laboratory of Brigitte Berger-Bächi is supported by Swiss National Science Foundation grant 32-63552.00.

We thank Regine Hakenbeck for helpful suggestions.

#### ADDENDUM IN PROOF

Recent publications of two important crystal structures provide a basis for further research: D. Lim and N. C. Strynadka, *Nat. Struct. Biol.* **9**:870–876, 2002; T. Benson et al., *Structure* (Cambridge) **10**:1107–1115, 2002.

#### REFERENCES

- Alborn, W. E. J., J. Hoskins, S. Unal, J. E. Flokowitsch, C. A. Hayes, J. E. Dotzlauf, W. K. Yeh, and P. L. Skatrud. 1996. Cloning and characterization of *femA* and *femB* from *Staphylococcus epidermidis*. *Gene* **180**:177–181.
- al-Obeid, S., D. Billot-Klein, J. van Heijenoort, E. Collatz, and L. Gutmann. 1992. Replacement of the essential penicillin-binding protein 5 by high-molecular mass PBPs may explain vancomycin- $\beta$ -lactam synergy in low-level vancomycin-resistant *Enterococcus faecium* D366. *FEMS Microbiol. Lett.* **70**:79–84.
- Altschul, S. F., T. L. Madden, A. A. Schäffer, J. Zhang, Z. Zhang, W. Miller, and D. J. Lipman. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res.* **25**:3389–3402.
- Baba, T., F. Takeuchi, M. Kuroda, H. Yuzawa, K. Aoki, A. Oguchi, Y. Nagai, N. Iwama, K. Asano, T. Naimi, H. Kuroda, L. Cui, K. Yamamoto, and K. Hiramatsu. 2002. Genome and virulence determinants of high virulence community-acquired MRSA. *Lancet* **359**:1819–1827.
- Barber, M. 1961. Methicillin-resistant staphylococci. *J. Clin. Pathol.* **14**:385–393.
- Barg, N., H. Chambers, and D. Kernodle. 1991. Borderline susceptibility to antistaphylococcal penicillins is not conferred exclusively by the overproduction of  $\beta$ -lactamase. *Antimicrob. Agents Chemother.* **35**:1975–1979.
- Beatson, S., G. Sloan, and R. Simmonds. 1998. Zoonin A immunity factor: a *femA*-like gene found in a group C streptococcus. *FEMS Microbiol. Lett.* **163**:73–77.
- Berger-Bächi, B. 1989. Genetics of methicillin resistance in *Staphylococcus aureus*. *J. Antimicrob. Chemother.* **23**:671–673.
- Berger-Bächi, B. 1983. Insertional inactivation of staphylococcal methicillin resistance by Tn551. *J. Bacteriol.* **154**:479–487.
- Berger-Bächi, B., L. Barberis-Maino, A. Strässle, and F. H. Kayser. 1989. FemA, a host-mediated factor essential for methicillin resistance in *Staphylococcus aureus*: molecular cloning and characterization. *Mol. Gen. Genet.* **219**:263–269.
- Berger-Bächi, B., and S. Rohrer. 2002. Control of methicillin resistance in *Staphylococcus aureus*. *Arch. Microbiol.* **178**:165–171.
- Berger-Bächi, B., A. Strässle, J. E. Gustafson, and F. H. Kayser. 1992. Mapping and characterization of multiple chromosomal factors involved in methicillin resistance in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **36**:1367–1373.
- Beukes, M., and J. W. Hastings. 2001. Self-protection against cell wall hydrolysis in *Streptococcus milleri* NMSCC 061 and analysis of the millericin B operon. *Appl. Environ. Microbiol.* **67**:3888–3896.
- Bierne, H., S. K. Mazmanian, M. Trost, M. G. Pucciarelli, G. Liu, P. Dehoux, L. Jansch, F. G. Portillo, O. Schneewind, and P. Cossart. 2002. Inactivation of the *srtA* gene in *Listeria monocytogenes* inhibits anchoring of surface proteins and affects virulence. *Mol. Microbiol.* **43**:869–881.
- Billot-Klein, D., D. Shlaes, D. Bryant, D. Bell, J. van Heijenoort, and L. Gutmann. 1996. Peptidoglycan structure of *Enterococcus faecium* expressing vancomycin resistance of the VanB type. *Biochem. J.* **313**:711–715.
- Bouhss, A., N. Josseaume, D. Allan, M. Crouvoisier, L. Gutmann, J.-L. Mainardi, D. Mengin-Lecreulx, J. van Heijenoort, and M. Arthur. 2001. Identification of the UDP-MurNAc-pentapeptide: L-alanine ligase for synthesis of branched peptidoglycan precursors in *Enterococcus faecalis*. *J. Bacteriol.* **183**:5122–5127.
- Bugg, T. 1999. Bacterial peptidoglycan biosynthesis and its inhibition, p. 241–294. In M. Pinto (ed.), *Comprehensive natural products chemistry*, vol. 3. Elsevier, Oxford, United Kingdom.
- Bumsted, R. M., J. L. Dahl, D. Soll, and J. L. Strominger. 1968. Biosynthesis of the peptidoglycan of bacterial cell walls. X. Further study of the glycyl transfer ribonucleic acids active in peptidoglycan synthesis in *Staphylococcus aureus*. *J. Biol. Chem.* **243**:779–782.
- Centers for Disease Control and Prevention. 2002. *Staphylococcus aureus* resistant to vancomycin—United States, 2002. *Morb. Mortal. Wkly. Rep.* **51**:565–567.
- DeHart, H. P., H. E. Heath, L. S. Heath, P. A. LeBlanc, and G. L. Sloan. 1995. The lysostaphin endopeptidase resistance gene (*epi*) specifies modification of peptidoglycan cross bridges in *Staphylococcus simulans* and *Staphylococcus aureus*. *Appl. Environ. Microbiol.* **61**:1475–1479.
- de Jonge, B. L., S. Handwerger, and D. Gage. 1996. Altered peptidoglycan composition in vancomycin-resistant *Enterococcus faecalis*. *Antimicrob. Agents Chemother.* **40**:863–869.
- de Jonge, B. L. M., Y. S. Chang, N. Xu, and D. Gage. 1996. Effect of exogenous glycine on peptidoglycan composition and resistance in a methicillin-resistant *Staphylococcus aureus* strain. *Antimicrob. Agents Chemother.* **40**:1498–1503.
- de Jonge, B. L. M., D. Gage, and N. Xu. 2002. The carboxyl terminus of peptidoglycan stem peptides is a determinant for methicillin resistance in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **46**:3151–3155.
- de Jonge, B. L. M., T. Sidow, Y. S. Chang, H. Labischinski, B. Berger-Bächi, D. A. Gage, and A. Tomasz. 1993. Altered mureptide composition in *Staphylococcus aureus* strains with an inactivated *femA* locus. *J. Bacteriol.* **175**:2779–2782.
- de Jonge, B. L. M., and A. Tomasz. 1993. Abnormal peptidoglycan produced in a methicillin-resistant strain of *Staphylococcus aureus* grown in the presence of methicillin: functional role for penicillin-binding protein 2A in cell wall synthesis. *Antimicrob. Agents Chemother.* **37**:342–346.
- de Lencastre, H., and A. Tomasz. 1994. Reassessment of the number of auxiliary genes essential for expression of high-level methicillin resistance in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **38**:2590–2598.
- Dessen, A., N. Mouz, E. Gordon, J. Hopkins, and O. Dideberg. 2001. Crystal structure of PBP2x from a highly penicillin-resistant *Streptococcus pneumoniae* clinical isolate. *J. Biol. Chem.* **276**:45106–45112.
- Ehlert, K., W. Schröder, and H. Labischinski. 1997. Specificities of FemA and FemB for different glycine residues: FemB cannot substitute for FemA

- in staphylococcal peptidoglycan pentaglycine side chain formation. *J. Bacteriol.* **179**:7573–7576.
29. Ehlert, K., M. Tschierske, C. Mori, W. Schröder, and B. Berger-Bächi. 2000. Site-specific serine incorporation by Lf and Epr into positions 3 and 5 of the staphylococcal peptidoglycan interpeptide bridge. *J. Bacteriol.* **182**:2635–2638.
  30. Filipe, S. R., E. Severina, and A. Tomasz. 2000. Distribution of the mosaic structured *murM* genes among natural populations of *Streptococcus pneumoniae*. *J. Bacteriol.* **182**:6798–6805.
  31. Filipe, S. R., E. Severina, and A. Tomasz. 2001. Functional analysis of *Streptococcus pneumoniae* MurM reveals the region responsible for its specificity in the synthesis of branched cell wall peptides. *J. Biol. Chem.* **276**:39618.
  32. Filipe, S. R., E. Severina, and A. Tomasz. 2001. The role of *murMN* operon in penicillin resistance and antibiotic tolerance of *Streptococcus pneumoniae*. *Microb. Drug Resist.* **7**:303–316.
  33. Filipe, S. R., and A. Tomasz. 2000. Inhibition of the expression of penicillin resistance in *Streptococcus pneumoniae* by inactivation of cell wall muropeptide branching genes. *Proc. Natl. Acad. Sci. USA* **97**:4891–4896.
  34. Fontana, R., M. Aldegheri, M. Ligozzi, H. Lopez, A. Sucari, and G. Satta. 1994. Overproduction of a low-affinity penicillin-binding protein and high-level ampicillin resistance in *Enterococcus faecium*. *Antimicrob. Agents Chemother.* **38**:1980–1983.
  35. Fontana, R., P. Canepari, M. M. Lleo, and G. Satta. 1990. Mechanisms of resistance of enterococci to beta-lactam antibiotics. *Eur. J. Clin. Microbiol. Infect. Dis.* **9**:103–105.
  36. Garcia-Bustos, J., and A. Tomasz. 1990. A biological price of antibiotic resistance: major changes in the peptidoglycan structure of penicillin-resistant pneumococci. *Proc. Natl. Acad. Sci. USA* **87**:5415–5419.
  37. Ghuysen, J.-M. 1997. Penicillin-binding proteins. Wall peptidoglycan assembly and resistance to penicillin: facts, doubts and hopes. *Int. J. Antimicrob. Agents* **8**:45–60.
  38. Giesbrecht, P., T. Kersten, H. Maidhof, and J. Wecke. 1998. Staphylococcal cell wall: morphogenesis and fatal variations in the presence of penicillin. *Microbiol. Mol. Biol. Rev.* **62**:1371–1414.
  39. Goffin, C., and J. M. Ghuysen. 1998. Multimodular penicillin binding proteins: an enigmatic family of orthologs and paralogs. *Microbiol. Mol. Biol. Rev.* **62**:1079–1093.
  40. Gordon, E., N. Mouz, E. Duée, and O. Dideberg. 2000. The crystal structure of the penicillin-binding protein 2x from *Streptococcus pneumoniae* and its acyl-enzyme form: implication in drug resistance. *J. Mol. Biol.* **299**:477–485.
  41. Grebe, T., and R. Hakenbeck. 1996. Penicillin-binding proteins 2b and 2x of *Streptococcus pneumoniae* are primary resistance determinants for different classes of beta-lactam antibiotics. *Antimicrob. Agents Chemother.* **40**:829–834.
  42. Gutmann, L., S. al-Obeid, D. Billot-Klein, M. L. Guerrier, and E. Collatz. 1994. Synergy and resistance to synergy between beta-lactam antibiotics and glycopeptides against glycopeptide-resistant strains of *Enterococcus faecium*. *Antimicrob. Agents Chemother.* **38**:824–829.
  43. Hackbarth, C. J., and H. F. Chambers. 1989. Methicillin-resistant staphylococci: genetics and mechanisms of resistance. *Antimicrob. Agents Chemother.* **33**:991–994.
  44. Hakenbeck, R., N. Balmelle, B. Weber, C. Gardes, W. Keck, and A. de Saizieu. 2001. Mosaic genes and mosaic chromosomes: intra- and interspecies genomic variation of *Streptococcus pneumoniae*. *Infect. Immun.* **69**:2477–2486.
  45. Hakenbeck, R., and J. Coyette. 1998. Resistant penicillin-binding proteins. *Cell. Mol. Life Sci.* **54**:332–340.
  46. Hakenbeck, R., T. Grebe, D. Zahner, and J. B. Stock. 1999. Beta-lactam resistance in *Streptococcus pneumoniae*: penicillin-binding proteins and non-penicillin-binding proteins. *Mol. Microbiol.* **33**:673–678.
  47. Hakenbeck, R., A. König, I. Kern, M. van der Linden, W. Keck, D. Billot-Klein, R. Legrand, B. Schoot, and L. Gutmann. 1998. Acquisition of five high- $M_r$  penicillin-binding protein variants during transfer of high-level beta-lactam resistance from *Streptococcus mitis* to *Streptococcus pneumoniae*. *J. Bacteriol.* **180**:1831–1840.
  48. Hegde, S. S., and T. E. Shrader. 2001. FemABX family members are novel nonribosomal peptidyltransferases and important pathogen-specific drug targets. *J. Biol. Chem.* **276**:6998–7003.
  49. Henze, U., T. Sidow, J. Wecke, H. Labischinski, and B. Berger-Bächi. 1993. Influence of *femB* on methicillin resistance and peptidoglycan metabolism in *Staphylococcus aureus*. *J. Bacteriol.* **175**:1612–1620.
  50. Henze, U. U., M. Roos, and B. Berger-Bächi. 1996. Effects of penicillin-binding protein 4 overproduction in *Staphylococcus aureus*. *Microb. Drug Resist. Mech. Epidemiol. Dis.* **2**:193–199.
  51. Hiramatsu, K., L. Cui, M. Kuroda, and T. Ito. 2001. The emergence and evolution of methicillin-resistant *Staphylococcus aureus*. *Trends Microbiol.* **9**:486–493.
  52. Holt, J. 1994. Bergey's manual of determinative bacteriology, 9th ed. The Williams & Wilkins Co., Baltimore, Md.
  53. Höltje, J. V. 1996. A hypothetical holoenzyme involved in the replication of the murein sacculus of *Escherichia coli*. *Microbiology (United Kingdom)* **142**:1911–1918.
  54. Ito, T., Y. Katayama, and K. Hiramatsu. 1999. Cloning and nucleotide sequence determination of the entire *mec* DNA of pre-methicillin-resistant *Staphylococcus aureus* N315. *Antimicrob. Agents Chemother.* **43**:1449–1458.
  55. Jamin, M., R. Hakenbeck, and J. M. Frère. 1993. Penicillin binding protein 2x as a major contributor to intrinsic beta-lactam resistance of *Streptococcus pneumoniae*. *FEBS Lett.* **331**:101–104.
  56. Kamiryo, T., and M. Matsubashi. 1972. The biosynthesis of the cross-linking peptides in the cell wall peptidoglycan of *Staphylococcus aureus*. *J. Biol. Chem.* **247**:6306–6311.
  57. Kamiryo, T., and M. Matsubashi. 1969. Sequential addition of glycine from glycyl-tRNA to the lipid-linked precursors of cell wall peptidoglycan in *Staphylococcus aureus*. *Biochem. Biophys. Res. Commun.* **36**:215–222.
  58. Katayama, Y., T. Ito, and K. Hiramatsu. 2000. A new class of genetic element, staphylococcal cassette chromosome *mec*, encodes methicillin resistance in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **44**:1549–1555.
  59. Kell, C. M., U. K. Sharma, C. G. Dowson, C. Town, T. S. Balganes, and B. G. Spratt. 1993. Deletion analysis of the essentiality of penicillin-binding protein-1A, penicillin-binding protein-2B and penicillin-binding protein-2X of *Streptococcus pneumoniae*. *FEMS Microbiol. Lett.* **106**:171–175.
  60. Kopp, U., M. Roos, J. Wecke, and H. Labischinski. 1996. Staphylococcal peptidoglycan interpeptide bridge biosynthesis: a novel antistaphylococcal target? *Microb. Drug Resist.* **2**:29–41.
  61. Laible, G., and R. Hakenbeck. 1991. Five independent combinations of mutations can result in low-affinity penicillin-binding protein 2x of *Streptococcus pneumoniae*. *J. Bacteriol.* **173**:6986–6990.
  62. Ling, B. D., and B. Berger-Bächi. 1998. Increased overall antibiotic susceptibility in *Staphylococcus aureus femAB* null mutants. *Antimicrob. Agents Chemother.* **42**:936–938.
  63. Ma, X. X., T. Ito, C. Tiensasitorn, M. Jamklang, P. Chongtrakool, S. Boyle-Vavra, R. S. Daum, and K. Hiramatsu. 2002. Novel type of staphylococcal cassette chromosome *mec* identified in community-acquired methicillin-resistant *Staphylococcus aureus* strains. *Antimicrob. Agents Chemother.* **46**:1147–1152.
  64. Maidhof, H., B. Reinicke, P. Blümel, B. Berger-Bächi, and H. Labischinski. 1991. *femA*, which encodes a factor essential for expression of methicillin resistance, affects glycine content of peptidoglycan in methicillin-resistant and methicillin-susceptible *Staphylococcus aureus* strains. *J. Bacteriol.* **173**:3507–3513.
  65. Matsubashi, M., C. Dietrich, and J. Strominger. 1965. Incorporation of glycine into the cell wall glycopeptide in *Staphylococcus aureus*: role of sRNA and lipid intermediates. *Proc. Natl. Acad. Sci. USA* **54**:587–594.
  66. Matsubashi, M., C. P. Dietrich, and J. L. Strominger. 1967. Biosynthesis of the peptidoglycan of bacterial cell walls. III. The role of soluble ribonucleic acid and of lipid intermediates in glycine incorporation in *Staphylococcus aureus*. *J. Biol. Chem.* **242**:3191–3206.
  67. Mazmanian, S. K., G. Liu, H. Ton-That, and O. Schneewind. 1999. *Staphylococcus aureus* sortase, an enzyme that anchors surface proteins to the cell wall. *Science* **285**:760–763.
  68. Mazmanian, S. K., H. Ton-That, K. Su, and O. Schneewind. 2002. An iron-regulated sortase anchors a class of surface protein during *Staphylococcus aureus* pathogenesis. *Proc. Natl. Acad. Sci. USA* **99**:2293–2298.
  69. Mouz, N., E. Gordon, A. M. Di Guilmi, I. Petit, Y. Petillot, Y. Dupont, R. Hakenbeck, T. Vernet, and O. Dideberg. 1998. Identification of a structural determinant for resistance to beta-lactam antibiotics in gram-positive bacteria. *Proc. Natl. Acad. Sci. USA* **95**:13403–13406.
  70. Murray, T., D. L. Popham, P. Setlow, A. M. Smith, K. P. Klugman, R. Hakenbeck, and J. Coyette. 1996. Identification and characterization of *phbC*, the gene encoding *Bacillus subtilis* penicillin-binding protein 3. *J. Bacteriol.* **178**:6001–6005.
  71. Nakagawa, J., S. Tamaki, S. Tomioka, and M. Matsubashi. 1984. Functional biosynthesis of cell wall peptidoglycan by polymorphic bifunctional polypeptides. Penicillin-binding protein 1Bs of *Escherichia coli* with activities of transglycosylase and transpeptidase. *J. Biol. Chem.* **259**:13937–13946.
  72. Navarre, W. W., and O. Schneewind. 1994. Proteolytic cleavage and cell wall anchoring at the LPXTG motif of surface proteins in gram-positive bacteria. *Mol. Microbiol.* **14**:115–121.
  73. Navarre, W. W., and O. Schneewind. 1999. Surface proteins of gram-positive bacteria and mechanisms of their targeting to the cell wall envelope. *Microbiol. Mol. Biol. Rev.* **63**:174–229.
  74. Novick, R. P. 1996. Possible alternatives to standard antibiotics in the management of infections with antibiotic-resistant organisms, p. 175–191. In C. F. Amabile-Cuevas (ed.), *Antibiotic resistance: from molecular basics to therapeutic options*. R. G. Landes Company, Austin, Tex.
  75. Page, R. D. 1996. TreeView: an application to display phylogenetic trees on personal computers. *Comput. Appl. Biosci.* **12**:357–358.
  76. Patti, J. M., and M. Höök. 1994. Microbial adhesins recognizing extracellular matrix macromolecules. *Curr. Opin. Cell Biol.* **6**:752–758.
  77. Perry, A. M., H. Ton-That, S. K. Mazmanian, and O. Schneewind. 2002.



- Anchoring of surface proteins to the cell wall of *Staphylococcus aureus*. III. Lipid II is an in vivo peptidoglycan substrate for sortase-catalyzed surface protein anchoring. *J. Biol. Chem.* **277**:16241–16248.
78. Petinaki, E., G. Dimitracopoulos, and I. Spiliopoulou. 2001. Decreased affinity of PBP3 to methicillin in a clinical isolate of *Staphylococcus epidermidis* with borderline resistance to methicillin and free of the *mecA* gene. *Microb. Drug Resist.* **7**:297–300.
  79. Pinho, M. G., S. R. Filipe, H. de Lencastre, and A. Tomasz. 2001. Complementation of the essential peptidoglycan transpeptidase function of penicillin-binding protein 2 (PBP2) by the drug resistance protein PBP2A in *Staphylococcus aureus*. *J. Bacteriol.* **183**:6525–6531.
  80. Piras, G., D. Raze, A. el Kharroubi, D. Hastir, S. Engelbert, J. Coyette, and J. M. Ghuysen. 1993. Cloning and sequencing of the low-affinity penicillin-binding protein 3r-encoding gene of *Enterococcus hirae* S185: modular design and structural organization of the protein. *J. Bacteriol.* **175**:2844–2852.
  81. Pootoolal, J., M. G. Thomas, C. G. Marshall, J. M. Neu, B. K. Hubbard, C. T. Walsh, and G. D. Wright. 2002. Assembling the glycopeptide antibiotic scaffold: the biosynthesis of A47934 from *Streptomyces toyocaensis* NRRL15009. *Proc. Natl. Acad. Sci. USA* **99**:8962–8967.
  82. Raze, D., O. Dardenne, S. Hallut, M. Martinezbueno, J. Coyette, and J. M. Ghuysen. 1998. The gene encoding the low-affinity penicillin-binding protein 3r in *Enterococcus hirae* S185R is borne on a plasmid carrying other antibiotic resistance determinants. *Antimicrob. Agents Chemother.* **42**:534–539.
  83. Reichmann, P., A. Konig, J. Linares, F. Alcaide, F. C. Tenover, L. McDougal, S. Swidsinski, and R. Hakenbeck. 1997. A global gene pool for high-level cephalosporin resistance in commensal *Streptococcus* species and *Streptococcus pneumoniae*. *J. Infect. Dis.* **176**:1001–1012.
  84. Rohrer, S., K. Ehlert, M. Tschierske, H. Labischinski, and B. Berger-Bächi. 1999. The essential *Staphylococcus aureus* gene *fnhB* is involved in the first step of peptidoglycan pentaglycine interpeptide formation. *Proc. Natl. Acad. Sci. USA* **96**:9351–9356.
  85. Ruzin, A., A. Severin, F. Ritacco, K. Tabei, G. Singh, P. A. Bradford, M. M. Siegel, S. J. Projan, D. M. Shlaes, A. M. Perry, H. Ton-That, S. K. Mazmanian, and O. Schneewind. 2002. Further evidence that a cell wall precursor [C(55)-MurNAc-(peptide)-GlcNAc] serves as an acceptor in a sorting reaction. *J. Bacteriol.* **184**:2141–2147.
  86. Ryffel, C., A. Strässle, F. H. Kayser, and B. Berger-Bächi. 1994. Mechanisms of heteroresistance in methicillin-resistant *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **38**:724–728.
  87. Sauvage, E., F. Kerff, E. Fonze, R. Hermann, B. Schoot, J.-P. Marquette, Y. Taburet, D. Prevost, J. Dumas, G. Leonard, P. Stefanic, J. Coyette, and P. Charlier. 2002. The 2.4 Å crystal structure of the penicillin-resistant penicillin-binding protein PBP5fm from *Enterococcus faecium* in complex with benzylpenicillin. *Cell. Mol. Life Sci.* **59**:1223–1232.
  88. Schleifer, K. H., and O. Kandler. 1972. Peptidoglycan types of bacterial cell walls and their taxonomic implications. *Bacteriol. Rev.* **36**:407–477.
  89. Severin, A., A. M. Figueiredo, and A. Tomasz. 1996. Separation of abnormal cell wall composition from penicillin resistance through genetic transformation of *Streptococcus pneumoniae*. *J. Bacteriol.* **178**:1788–1792.
  90. Severin, A., and A. Tomasz. 1996. Naturally occurring peptidoglycan variants of *Streptococcus pneumoniae*. *J. Bacteriol.* **178**:168–174.
  91. Sifaoui, F., M. Arthur, L. Rice, and L. Gutmann. 2001. Role of penicillin-binding protein 5 in expression of ampicillin resistance and peptidoglycan structure in *Enterococcus faecium*. *Antimicrob. Agents Chemother.* **45**:2594–2597.
  92. Signoretto, C., M. Boaretti, and P. Canepari. 1998. Peptidoglycan synthesis by *Enterococcus faecalis* penicillin binding protein 5. *Arch. Microbiol.* **170**:185–190.
  93. Signoretto, C., P. Canepari, A. M. Perry, H. Ton-That, S. K. Mazmanian, and O. Schneewind. 2000. Paradoxical effect of inserting, in *Enterococcus faecalis* penicillin-binding protein 5, an amino acid box responsible for low affinity for penicillin in *Enterococcus faecium*. *Arch. Microbiol.* **173**:213–219.
  94. Simmonds, R. S., W. J. Simpson, and J. R. Tagg. 1997. Cloning and sequence analysis of *zooA*, a *Streptococcus zooepidemicus* gene encoding a bacteriocin-like inhibitory substance having a domain structure similar to that of lysostaphin. *Gene* **189**:255–261.
  95. Smith, A. M., and K. P. Klugman. 2001. Alterations in MurM, a cell wall mureptide branching enzyme, increase high-level penicillin and cephalosporin resistance in *Streptococcus pneumoniae*. *Antimicrob. Agents Chemother.* **45**:2393–2396.
  96. Smith, A. M., K. P. Klugman, R. Hakenbeck, and J. Coyette. 2000. Non-penicillin-binding protein mediated high-level penicillin and cephalosporin resistance in a Hungarian clone of *Streptococcus pneumoniae*. *Microb. Drug Resist.* **6**:105–110.
  97. Strominger, J., and J. Ghuysen. 1967. Mechanisms of enzymatic bacteriolysis. Cell walls of bacteria are solubilized by action of either specific carboxylhydrolases or specific peptidases. *Science* **156**:213–221.
  98. Sugai, M. 1997. Peptidoglycan hydrolases of the staphylococci. *J. Infect. Chemother.* **3**:113–127.
  99. Sugai, M., T. Fujiwara, H. Komatsuzawa, and H. Suganaka. 1998. Identification and molecular characterization of a gene homologous to *epr* (endopeptidase resistance gene) in *Staphylococcus aureus*. *Gene* **224**:67–75.
  100. Sugai, M., T. Fujiwara, K. Ohta, H. Komatsuzawa, M. Ohara, and H. Suganaka. 1997. *epr*, which encodes glycylglycine endopeptidase resistance, is homologous to *femAB* and affects serine content of peptidoglycan cross bridges in *Staphylococcus capitis* and *Staphylococcus aureus*. *J. Bacteriol.* **179**:4311–4318.
  101. Sugai, M., S. Yamada, S. Nakashima, H. Komatsuzawa, A. Matsumoto, T. Oshida, and H. Suganaka. 1997. Localized perforation of the cell wall by a major autolysin: *atl* gene products and the onset of penicillin-induced lysis of *Staphylococcus aureus*. *J. Bacteriol.* **179**:2958–2962.
  102. Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res.* **22**:4673–4680.
  103. Thumm, G., and F. Götz. 1997. Studies on polysostaphin processing and characterization of the lysostaphin immunity factor (Lif) of *Staphylococcus simulans* biovar staphylohyticus. *Mol. Microbiol.* **23**:1251–1265.
  104. Tipper, D., and J. Strominger. 1965. Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-D-alanyl-D-alanine. *Proc. Natl. Acad. Sci. USA* **54**:1133.
  105. Tomasz, A. 1986. Penicillin-binding proteins and the antibacterial effectiveness of beta-lactam antibiotics. *Rev. Infect. Dis.* **8**(Suppl. 3):S260–S278.
  106. Tomasz, A., H. B. Drugeon, H. M. de Lencastre, D. Jabes, and L. McDougal. 1989. New mechanism for methicillin resistance in *Staphylococcus aureus*: clinical isolates that lack the PBP2a gene and contain normal penicillin-binding proteins with modified penicillin-binding capacity. *Antimicrob. Agents Chemother.* **33**:1869–1874.
  107. Ton-That, H., H. Labischinski, B. Berger-Bächi, and O. Schneewind. 1998. Anchor structure of staphylococcal surface proteins. III. Role of the *femA*, *femB*, and *femX* factors in anchoring surface proteins to the bacterial cell wall. *J. Biol. Chem.* **273**:29143–29149.
  108. Tschierske, M., K. Ehlert, A. M. Stranden, and B. B. Berger. 1997. Lif, the lysostaphin immunity factor, complements FemB in staphylococcal peptidoglycan interpeptide bridge formation. *FEMS Microbiol. Lett.* **153**:261–264.
  109. Tschierske, M., C. Mori, S. Rohrer, K. Ehlert, K. J. Shaw, and B. Berger-Bächi. 1999. Identification of three additional *femAB*-like open reading frames in *Staphylococcus aureus*. *FEMS Microbiol. Lett.* **171**:97–102.
  110. Umamoto, T., T. Ota, H. Sagawa, K. Kato, H. Takada, M. Tsujimoto, A. Kawasaki, T. Ogawa, K. Harada, and S. Kotani. 1981. Chemical and biological properties of a peptidoglycan isolated from *Treponema pallidum* kasan. *Infect. Immun.* **31**:767–774.
  111. van Heijenoort, J. 1994. Biosynthesis of the bacterial peptidoglycan unit. In J.-M. Ghuysen and R. Hakenbeck (ed.), *Bacterial cell wall*. Elsevier Science B.V., Amsterdam, The Netherlands.
  112. Vannuffel, P., M. Hersterspreute, M. Bouyer, B. Vandercam, M. Philippe, and J.-L. Gala. 1999. Molecular characterization of *femA* from *Staphylococcus hominis* and *Staphylococcus saprophyticus*, and *femA*-based discrimination of staphylococcal species. *Res. Microbiol.* **150**:129–141.
  113. Wang, J. E., P. F. Jorgensen, M. Almlof, C. Thiemermann, S. J. Foster, A. O. Aasen, and R. Solberg. 2000. Peptidoglycan and lipoteichoic acid from *Staphylococcus aureus* induce tumor necrosis factor alpha, interleukin 6 (IL-6), and IL-10 production in both T cells and monocytes in a human whole blood model. *Infect. Immun.* **68**:3965–3970.
  114. Weber, B., K. Ehlert, A. Diehl, P. Reichmann, H. Labischinski, and R. Hakenbeck. 2000. The *fib* locus in *Streptococcus pneumoniae* is required for peptidoglycan crosslinking and PBP-mediated  $\beta$ -lactam resistance. *FEMS Microbiol. Lett.* **188**:81–85.
  115. Yanagihara, Y., K. Kamisango, S. Yasuda, S. Kobayashi, I. Mifuchi, I. Azuma, Y. Yamamura, and R. Johnson. 1984. Chemical compositions of cell walls and polysaccharide fractions of spirochetes. *Microbiol. Immunol.* **28**:535–544.
  116. Yoshimura, A., E. Lien, R. R. Ingalls, E. Tuomanen, R. Dziarski, and D. Golubeva. 1999. Cutting edge: recognition of gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. *J. Immunol.* **163**:1–5.
  117. Zhao, G., W. K. Yeh, R. H. Carnahan, J. Flokowitsch, T. I. Meier, W. E. Alborn, Jr., G. W. Becker, S. R. Jaskunas, A. M. Smith, K. P. Klugman, R. Hakenbeck, and J. Coyette. 1997. Biochemical characterization of penicillin-resistant and -sensitive penicillin-binding protein 2x transpeptidase activities of *Streptococcus pneumoniae* and mechanistic implications in bacterial resistance to beta-lactam antibiotics. *J. Bacteriol.* **179**:4901–4908.